Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Multifocal pyoderma gangrenosum mimicking disseminated cutaneous leishmaniasis ‒ a diagnostic challenge.
An Bras Dermatol
January 2025
Department of Dermatology, Hospital de Câncer de Barretos, Barretos, SP, Brazil; Department of Dermatology, Faculdade de Ciências da Saúde de Barretos Dr. Paulo Prata, Barretos, SP, Brazil.
First-in-human, multicenter, open-label, phase I study of ATOR-1017 (evunzekibart), a 4-1BB antibody, in patients with advanced solid malignancies.
J Immunother Cancer
January 2025
Department of Oncology, Uppsala University Hospital, Uppsala, Sweden
Background: ATOR-1017 (evunzekibart) is a human agonistic immunoglobulin G4 antibody targeting the costimulatory receptor 4-1BB (CD137). ATOR-1017 activates T cells and natural killer cells in the tumor environment, leading to immune-mediated tumor cell death.
Methods: In this first-in-human, multicenter, phase I study, ATOR-1017 was administered intravenously every 21 days as a monotherapy to patients with advanced, unresectable solid tumors having received multiple standard-of-care treatments.
Subtype specific alterations in the skin microbiome of patients with cutaneous T-cell lymphoma.
J Invest Dermatol
January 2025
Department of Dermato-venereology, Bispebjerg Hospital, University of Copenhagen, Denmark.
Production of exosomal nanoparticles containing antigenic peptides LACK, KMP11, TSA and LmSTI1 of L. major and evaluation of their immunoprophylactic effect against L. major infection in a murine infection model.
Microb Pathog
January 2025
Department of Medical Parasitology and Mycology, School of Public Health, Tehran University of Medical Sciences, Tehran, Iran; Center for Research of Endemic Parasites of Iran (CREPI), Tehran University of Medical Sciences, Tehran, Iran. Electronic address:
Sex differences in survival from melanoma of the skin: The role of age, anatomic location and stage at diagnosis: A CONCORD-3 study in 59 countries.
Eur J Cancer
January 2025
Cancer Survival Group, London School of Hygiene and Tropical Medicine, Keppel Street, London WC1E 7HT, UK.
Background: CONCORD-3 highlighted wide disparities in population-based 5-year net survival for cutaneous melanoma during 2000-2014. Studies showed a survival advantage in women, but the reasons are not completely understood. We aim to estimate trends in age-standardised 5-year net survival by sex and to examine the role of age, anatomic location and stage on the survival advantage for women worldwide.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!